Composition for relieving hangovers

Abstract

Provided is a composition for relieving a hangover including as its active ingredients Corylus heterophylla Fisher nut extract, Alnus japonica Steud. stem extract and Sorbus commixta fruit extract. It is verified the composition for relieving a hangover according to the present disclosure reduces blood alcohol concentration more significantly than the composition for relieving a hangover including as its active ingredients Alnus japonica Steud. extract and Sorbus commixta extract as disclosed in Korean Patent Registration No. 181168 in in vivo tests (including animal testing and human experiment) and that has effects of considerably alleviating various hangover symptoms.

Claims

1. A composition for relieving a hangover comprising an effective amount of a synergistic combination of extracts consisting of: (a) 50-60% Corylus heterophylla Fisher nut extract produced by immersing dried, milled Corylus heterophylla Fisher nuts in hot water at 70° C., extracting for 12 hours at 80° C.-95° C., removing Corylus heterophylla Fisher nut extraction debris, concentrating under reduced pressure and drying the Corylus heterophylla Fisher nut extract; (b) at least 10% Alnus japonica Steud. stem extract produced by immersing dried, milled Alnus japonica Steud. stems in hot water at 70° C. and extracting for 12 hours at 80° C.-95° C., removing Alnus japonica Steud. stem extraction debris, concentrating under reduced pressure and drying the Alnus japonica Steud. stem extract; and (c) 10-30% Sorbus commixta fruit extract produced by immersing dried, milled Sorbus commixta fruit in hot water at 70° C. and extracting for 12 hours at 80° C.-95° C., removing Sorbus commixta fruit extraction debris, concentrating under reduced pressure and drying the Sorbus commixta fruit extract.

Description

DETAILED DESCRIPTION

(1) The term of ‘to extract/extracting/extraction’ used in the present disclosure refers to manipulation to take, using a solvent or a reagent, a specific substance out of a solid or a liquid material. In other words, it refers to manipulation to dissolve or separate only a specific substance in a mixture, for example, extracting a medicinal substance from a plant and the like using water or an organic solvent such as ethanol (ethyl alcohol) and ether.

(2) The term of ‘extract’ used in the present disclosure refers to a substance separated from a target raw material through the ordinary extracting process, as described above, and includes a liquid extract by using an extractant or its concentrate or its pulverized one. The extract of the present disclosure includes the whole of the extracts which show practically an identical effect by using the extractant as well as any other extractants. The extracting process of the present disclosure can be repeated several times and go through another ordinary concentration process. The extract according to the present disclosure can be manufactured into particles through another process such as vacuum distillation, lyophilization, spray drying and the like.

(3) The present disclosure provides the composition for relieving a hangover including as its active ingredients Corylus heterophylla Fisher nut extract, Alnus japonica Steud. stem extract and Sorbus commixta fruit extract.

(4) The composition according to the present disclosure can include purified water and, besides Corylus heterophylla Fisher nut extract, Alnus japonica Steud. stem extract and Sorbus commixta fruit extract as the active ingredients, edible plant extract such as liquorice and jujubes and honey, the natural sweetener.

(5) The composition for relieving a hangover including as its active ingredients Corylus heterophylla Fisher nut extract, Alnus japonica Steud. stem extract and Sorbus commixta fruit extract according to the present disclosure can be added to a health functional food for the purpose of hangover relieving while the composition for relieving a hangover according to the present disclosure can be used together with food raw materials and food additives when it is added to a food.

(6) According to the Act on Health Functional Food, Article 3, ‘a health functional food’ refers to a food manufactured (including being processed. The same hereinafter) by using a raw material or a substance having functionality useful to human bodies, where ‘functionality’ refers to controlling nutrients in relation to the human structure and functions or obtaining an effect useful to health use such as physiological action.

(7) Health functional foods to which the composition for relieving a hangover according to the present disclosure are not specifically limited. The foods can be, for example, beverages, soups, extracts, jellies, candies, chocolates, chewing gums and the like, to which sitologically accepted food additives can be added such as sweeteners, acidulants and flavorings.

(8) The Food Code issued by the Ministry of Food and Drug Safety of Korea sets forth Alnus japonica Steud. and Sorbus commixta as raw materials limitedly accepted for food. When a raw material which falls under the category limitedly accepted for food is added, the whole quantity of the material to add should be under 50% of the corresponding product (save for mixing water).

(9) When the composition for relieving a hangover according to the present disclosure is added to a food, 0.1 to 99.9 wt %, desirably 1 to 50 wt %, of the composition can be included in the food with reference to the whole quantity of the food (100 wt %) save for mixing water (purified water).

(10) When the food to which the composition of the present disclosure can be added is a beverage, the beverage is not restricted in terms of its ingredients save for the fact that the beverage includes as its active ingredient the composition according to the present disclosure and the beverage can further include food additives such as purified water, sweeteners, acidulants and flavorings like ordinary beverages.

(11) Components of the composition according to the present disclosure are as follows, as listed in Table 1.

(12) TABLE-US-00001 TABLE 1 Composition ratio Component (wt %) Component 1 Corylus heterophylla Fisher nut extract 50-70 Component 2 Alnus japonica Steud. stem extract 10-20 Component 3 Sorbus commixta fruit extract 10-30

(13) When the composition ratio (content) of each of the components falls short of the range, sufficient hangover relieving cannot be expected whereas, when it exceeds the range, there occurs an adverse effect to hangover relieving and it is not desirable in that it is not harmonized with other extracts in terms of taste. (Refer to Tables 3, 4, 6 and 7).

(14) The Supreme Court of Korea decided that “in the case an invention of a registered patent expresses numerically limit the range of a subject matter of another patent publicly known before the invention was applied, when the objectives and effects of the patented invention are extended from the publicly known patent with only difference between them in whether numerical limitation, if there arises no significant difference of effects near the limited numerical range the patented invention is nothing more than simple numerical limitation a person skilled in the art can appropriately select through ordinary and repeated experiments, thereby repudiating its inventive step. However, when the numerical limitation is just a complementary matter of the patented invention in that another subject matter is added so that inventive steps of the patented invention should be acknowledged, or when, even if the compositions of both of the inventions are identical save for the numerical limitation, the numerical limitation is significant as a technological tool for achieving an objective different from that of the publicly known invention and its effects are also different from those of the publicly known invention, the inventive steps of the patented invention shall not be denied by reason of the fact the numerical limitation has no critical significance.” (The Supreme Court of Korea, as announced on Aug. 19, 2008 2008HU4998 Decision).

(15) In the present disclosure, the Corylus heterophylla Fisher nut extract as a publicly unknown subject matter is added to the Alnus japonica Steud. stem extract and the Sorbus commixta fruit extract as publicly known subject matters. Therefore, the inventive step of the present disclosure should not be repudiated by reason that there is no critical significance of numerical limitation. However, the present disclosure presents animal testing and human experiment data around the range of its numerical limitation.

<Embodiment 1> Manufacture of the Corylus heterophylla Fisher Nut Extract

(16) 1-1. Corylus heterophylla Fisher nuts were collected, dried and milled. The milled nuts were immersed in 80% ethanol and extracted for 12 hours at 70° C. After that, extraction debris was removed, concentrated under reduced pressure and dried, thereby producing Corylus heterophylla Fisher nut extract in the shape of particles.

(17) 1-2. Corylus heterophylla Fisher nuts were collected, dried and milled. The milled nuts were immersed in hot water at 70° C. and extracted for 12 hours at 80-95° C. After that, extraction debris was removed, concentrated under reduced pressure and dried, thereby producing Corylus heterophylla Fisher nut extract in the shape of particles.

<Embodiment 2> Manufacture of the Alnus japonica Steud. Stem Extract

(18) 2-1. Alnus japonica Steud. stems were collected, dried and milled. The milled stems were immersed in 80% ethanol and extracted for 12 hours at 70° C. After that, extraction debris was removed, concentrated under reduced pressure and dried, thereby producing Alnus japonica Steud. stem extract in the shape of particles.

(19) 2-2. Alnus japonica Steud. stems were collected, dried and milled. The milled stems were immersed in hot water at 70° C. and extracted for 12 hours at 80-95° C. After that, extraction debris was removed, concentrated under reduced pressure and dried, thereby producing Alnus japonica Steud. stem extract in the shape of particles.

<Embodiment 3> Manufacture of the Sorbus commixta Fruit Extract

(20) 3-1. Sorbus commixta fruit was collected, dried and milled. The milled fruit was immersed in 80% ethanol and extracted for 12 hours at 70° C. After that, extraction debris was removed, concentrated under reduced pressure and dried, thereby producing Sorbus commixta fruit extract in the shape of particles.

(21) 3-2. Sorbus commixta fruit was collected, dried and milled. The milled fruit was immersed in hot water at 70° C. and extracted for 12 hours at 80-95° C. After that, extraction debris was removed, concentrated under reduced pressure and dried, thereby producing Sorbus commixta fruit extract in the shape of particles.

<Embodiment 4> Manufacture of the Liquid Composition

(22) 4-1. For animal testing, the composition according to the present disclosure was manufactured into liquid by adding 1,000 cc of distilled water to 100 g of the composition according to the composition ratios of embodiments ‘a’ through ‘e’ and comparative examples ‘a’ through ‘f’ as listed in Table 2.

(23) 4-2. For human experiment, the composition according to the present disclosure was manufactured into liquid by adding 1,000 cc of distilled water to 100 g of the composition according to the composition ratios of embodiments ‘a’ through ‘e’ and comparative examples ‘a’ through ‘f’ as listed in Table 2 and mixing 80 wt % of the produced liquid composition with 20 wt % of honey.

(24) TABLE-US-00002 TABLE 2 Corylus Alnus Sorbus heterophylla japonica commixta Fisher nut Steud. stem fruit extract extract extract Embodiments a 70 10 20 b 70 20 10 c 60 10 30 d 60 20 20 e 50 20 30 Comparative examples a 80 10 10 b 40 20 40 c — 30 70 d — 40 60 e — 50 50 f — 60 40 (unit: wt %)

<Experimental Example 1> Animal Testing

(25) Animal testing were referred to the Prof. Jong-Dae Kim's team of Department of Food Science & Biotechnology, College of Agriculture and Life Sciences, Kangwon National University and carried out there.

(26) 1-1. Test Description

(27) Animal to test: Ten male white rats (about 260 g per rat) were deployed in each treatment group.

(28) Control group: Groups were administered 11 specimens of the liquid compositions.

(29) Test spiritus: Chivas Regal (alcohol concentration: 40%)

(30) Ethanol administration dose: Single acute ethanol intoxication dose (4 g ethanol/1 kg body wt.)

(31) Liquid composition specimen administration dose: 2.5 g per 1 kg of body weight

(32) Blood drawing interval: 60, 90, 150 and 240 minutes after alcohol administration

(33) Specimen analyzed: Blood was drawn from eyeballs and serum was separated.

(34) Analysis method: Blood alcohol concentrations were analyzed according to the enzyme method.

(35) 1-2. Test Animals and their Treatment

(36) For the tests, postnatal white male Sprague Dawley rats (250 to 260 g of body weight per rat) were purchased from Daehan Biolink Co. Ltd. and adapted for 1 week at Kangwon National University Laboratory Animal Centre (22±2° C. of temperature; 50 to 55% of humidity; and 12-hour light/dark cycle regime). For the entire period of the tests the rats were provided with water and feed in unrestricted quantity.

(37) Ten of the adapted rats were distributed to each of the treatment groups. Chivas Regal (alcohol concentration: 40%) as test spritus was orally administered to the rats with reference to their body weight. The liquid composition specimens of Embodiment 4-1 were orally administered 30 minutes before or after ethanol administration.

(38) 1-3. 1.sub.st Test (Pre-Treatment)

(39) The liquid composition specimens were administered 30 minutes prior to alcohol administration and blood alcohol concentration was measured by drawing blood subsequent to 60, 90, 150 and 240 minutes after alcohol administration.

(40) 1-4. 2.sup.nd Test (Post-Treatment)

(41) Was performed 3 weeks after the 1.sup.st test was completed, where the liquid composition specimens were administered 30 minutes after alcohol administration and blood alcohol concentration was measured by drawing blood 90, 150 and 240 minutes after alcohol administration.

(42) 1-5. Blood Alcohol Concentration Analyses

(43) Blood was collected from eyeballs 60, 90, 150 and 240 min. after alcohol administration and put into a serum separation tube for serum separation by centrifugation (15,000 rpm, 10 min, 4° C.). Alcohol content was measured with an alcohol assay kit (Komabiotech, Korea). 2× yellow reaction mixture (90 μl) was added to the separated serum (10 μl). After being placed for incubation for 30 min, at 37° C., the expressed color formation was measured at 570 nm.

(44) Alcohol concentration (mM) was measured by putting measured light absorbance into the standard alcohol curve. For the standard curve, absorbance was measured according to the same method as above by diluting 10 mM of standard solution to 2,000, 1,000, 500, 250, 125, 62.5, 31.25, and 0 μM.

(45) 1-6. Statistical Analyses

(46) Test results were expressed by mean and standard deviation values (mean±SD) and statistical significance among the experimental groups was investigated (P<0.05) according to the one-way ANOVA test (Bonferroni test for post hoc multiple comparison) with GraphPad InStat software.

(47) 1-7. Results of the 1.sup.st Test (Specimen Administration 30 Minutes Before Alcohol Administration) are as Follows, as Listed in Table 3.

(48) TABLE-US-00003 TABLE 3 Composition (wt %) C. A. S. BAC (mean ± SD) (μM) ex- ex- ex- 60 min 90 min 150 min 240 min tract tract tract after AA after AA after AA after AA EM a 70 10 20 579 ± 52 442 ± 38 323.6 ± 26   315 ± 35 b 70 20 10 464 ± 37 389 ± 39   385 ± 40   310 ± 44 c 60 10 30 576.3 ± 122  477.9 ± 37   308.5 ± 50 309.7 ± 62 d 60 20 20 471 ± 21 459 ± 20   415 ± 16   389 ± 20 e 50 20 30 597.8 ± 53   492.1 ± 117  437.4 ± 76 415.7 ± 70 CE a 80 10 10  686 ± 100 568.3 ± 78   498.6 ± 81 442.8 ± 54 b 40 20 40 671.4 ± 29   622.3 ± 27   571.3 ± 34 549.6 ± 37 c — 30 70 656 ± 53 648 ± 54   588 ± 53   568 ± 53 d — 40 60 692.8 ± 40   669.4 ± 111   592.4 ± 116 542.3 ± 80 e — 50 50 695.5 ± 43   582.9 ± 55   579.8 ± 60 535.7 ± 56 f — 60 40 673 ± 89 669 ± 89   609 ± 87   581 ± 85

(49) When comparing Embodiment(EM)s ‘a’ through ‘e’ according to the present disclosure with Comparative example(CE)s ‘a’ and ‘b’ with composition ratios that are not included in EMs of the present disclosure, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes before alcohol administration (AA) showed blood alcohol concentration(BAC) from 60 minutes after AA decreased lower than that of CEs as follows: 11.0% minimum (EM ‘e’/CE ‘b’=597.8/671.4) and 32.4% maximum (EM ‘b’/CE ‘a’=464/686) 60 min after AA; 13.4% min (EM ‘e’/CE ‘a’=492.1/568.3) and 37.5% max (Em ‘b’/CE ‘b’=389/622.3) 90 min after AA; 12.3% min (EM ‘e’/CE ‘a’=437.4/498.6) and 46.0% max (EM ‘c’/CE ‘b’=308.5/571.3) 150 min after AA; and min 6.1% (EM ‘e’/CE ‘a’=415.7/442.8) and 43.6% max (EM ‘c’/CE ‘b’=309.7/549.6) 240 min after AA.

(50) When comparing EMs ‘a’ and ‘b’ according to the present disclosure with CEs ‘c’ through ‘f’ including only Alnus japonica Steud. stem extract and Sorbus commixta fruit extract as in Korean Patent Registration No. 181168, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes before AA showed BAC from 60 minutes after AA decreased lower than that of CEs as follows: 8.9% min (EM ‘e’/CE ‘c’=597.8/656) and 33.3% max (EM ‘b’/CE ‘e’=464/695.5) 60 min after AA; 15.6% min (EM ‘e’/CE ‘e’=492.1/582.9) and 41.9% max (EM ‘b’/CE ‘d’=389/669.4) 90 min after AA; 24.6% min (EM ‘e’/CE ‘e’=437.4/579.8) and 49.3% max (EM ‘c’/CE ‘f’=308.5/609) 150 min after AA; and 22.4% min (EM ‘e’/CE ‘e’=415.7/535.7) and 46.7% max (EM ‘c’/CE ‘f’=309.7/581) 240 min after AA.

(51) When EMs ‘a’ through ‘e’ according to the present disclosure compared with CE ‘d’ whose composition ratio is closest to that of Dawn 808 the Hangover Solution currently on the market by implementing Korean Patent Registration No. 181168, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes before AA showed BAC from 60 minutes after AA decreased lower than that of CE as follows: 13.7% min (EM ‘e’/CE ‘d’=597.8/692.8) and 33.0% max (EM ‘b’/CE ‘d’=464/692.8) 60 min after AA; 26.5% min (EM ‘e’/CE ‘d’=492.1/669.4) and 41.9% max (EM ‘b’/CE ‘d’=389/669.4) 90 min after AA; 26.2% min (EM ‘e’/CE ‘d’=437.4/592.4) and 48.0% max (EM ‘c’/CE ‘d’=308.5/592.4) 150 min after AA; and min 23.3% (EM ‘e’/CE ‘d’=415.7/542.3) and 42.9% max (EM ‘c’/CE ‘d’=309.7/542.3) 240 min after AA.

(52) 1-8. Results of the 2.sup.nd Test (Specimen Administration 30 Minutes after Alcohol Administration) are as Follows, as Listed in Table 4.

(53) TABLE-US-00004 TABLE 4 Composition (wt %) C. A. S. BAC (mean ± SD) (μM) ex- ex- ex- 90 min 150 min 240 min tract tract tract after AA after AA after AA EM a 70 10 20 567 ± 45 501 ± 32 399 ± 62 b 70 20 10 458 ± 45 416 ± 35 360 ± 39 c 60 10 30 451 ± 53 426 ± 49 301 ± 51 d 60 20 20 476 ± 48 434 ± 44 387 ± 39 e 50 20 30 546 ± 42 504 ± 45 455 ± 48 CE a 80 10 10 605 ± 57 537 ± 60 470 ± 56 b 40 20 40 588 ± 45 544 ± 46 504 ± 50 c — 30 70 643 ± 50 601 ± 53 551 ± 56 d — 40 60 628 ± 90 586 ± 94 567 ± 97 e — 50 50 614 ± 57 571 ± 57 540 ± 51 f — 60 40 613 ± 87 524 ± 75 514 ± 74

(54) When comparing EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘a’ and ‘b’ with composition ratios that are not included in EMs of the present disclosure, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes after AA showed BAC from 90 minutes after AA decreased lower than that of CEs as follows: 3.6% min (EM ‘a’/CE ‘b’=567/588) and 25.5% max (EM ‘c’/CE ‘a’=451/605) 90 min after AA; 6.1% min (EM ‘e’/CE ‘a’=504/537) and 23.5% max (EM ‘b’/CE b=416/544) 150 min after AA; and 3.2% min (EM ‘e’/CE ‘a’=455/470) and 40.3% max (EM ‘c’/CE ‘b’=301/504) 240 min after AA.

(55) When comparing EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘c’ through f including only Alnus japonica Steud. stem extract and Sorbus commixta fruit extract as in Korean Patent Registration No. 181168, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes after AA showed BAC from 90 minutes after AA decreased lower than that of CEs as follows: min 7.5% (EM ‘a’/CE ‘f’=567/613) and 29.9% max (EM ‘c’/CE ‘c’=451/643) 90 min after AA; 3.8% min (EM ‘e’/CE ‘f’=504/524) and 30.8% max (EM ‘b’/CE ‘c’=416/601) 150 min after AA; and 11.5% min (EM ‘e’/CE ‘f’=455/514) and 46.9% max (EM ‘c’/CE ‘d’=301/567) 240 min after AA.

(56) When EMs ‘a’ through ‘e’ according to the present disclosure compared with CE ‘d’ whose composition ratio is closest to that of Dawn 808 the Hangover Solution currently on the market by implementing Korean Patent Registration No. 181168, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes after AA showed BAC from 90 minutes after AA decreased lower than that of CE as follows: 9.7% min (EM ‘a’/CE ‘d’=567/628) and 28.2% (EM ‘c’/CE ‘d’=451/628) 90 min after AA; 14.0% min (EM ‘e’/CE ‘d’=504/586) and 29.0% max (EM ‘b’/CE ‘d’=416/586) 150 min after AA; and 19.8% min (EM ‘e’/CE ‘d’=455/567) and 46.9% max (EM ‘c’/CE ‘d’=301/567) 240 min after AA.

<Experimental Example 2> Human Experiment

(57) For human experiment, human subjects stayed in the patient rooms of Seoul Surgery Clinic in Dongsong-eup, Cheolwon-gun, Gangwon-do, Korea after giving their consent. They administered the liquid composition specimens before ethanol administration or after ethanol administration completion. Their blood was drawn by nurses after ethanol administration completion by time and BAC measurement was referred to Green Cross Corp.

(58) 2-1. Test Description

(59) Human subjects: as listed in Table 5

(60) TABLE-US-00005 TABLE 5 Participants Sex Name Age (yrs) Weight (kg) EM a M Han ** 33 54 b M Lee ** 36 90 c M Kim ** 38 57 d M Kim ** 34 67 e M Lee ** 39 90 CE a M Park ** 39 93 b M Lim ** 50 66 c M Jo ** 38 65 d M Yu ** 39 77 e M Song ** 47 88 f M Kim ** 43 71

(61) After quitting alcohol administration for 3 days, they commenced it at 6 PM: drinking continued for 30 minutes with munchies of 170 g of jerky and 200 g of peaches. AA: 3 g of Chivas Regal (alcohol concentration: 40%) per 1 kg of body weight 2.5 g of the liquid composition specimen of Embodiment 4-2 was administered per 1 kg of body weight.

(62) Blood drawing interval: 60, 90, 150 and 240 minutes after AA

(63) 2-2. 1.sup.st Test

(64) The liquid composition specimens were administered 30 minutes prior to alcohol administration and blood alcohol concentration was measured by drawing blood subsequent to 60, 90, 150 and 240 minutes after alcohol administration.

(65) 2-3. 2.sup.nd Test

(66) Was performed 3 days without AA after the 1.sup.st test was completed, where the liquid composition specimens were administered 30 minutes after AA completion (AAC) and BAC was measured by drawing blood 90, 150 and 240 minutes after AAC.

(67) 2-4. Results of the 1.sup.st Test (Specimen Administration 30 Minutes Before AA) are as Follows, as Listed in Table 6.

(68) TABLE-US-00006 TABLE 6 BAC, % Composition (wt %) 150 240 C. A. S. 60 min 90 min min min ex- ex- ex- after after after after tract tract tract AAC AAC AAC AAC EM a 70 10 20 0.118 0.090 0.048 0.020 b 70 20 10 0.112 0.073 0.030 0.013 c 60 10 30 0.100 0.051 0.022 0.011 d 60 20 20 0.107 0.064 0.024 0.012 e 50 20 30 0.115 0.079 0.045 0.019 CE a 80 10 10 0.127 0.096 0.058 0.039 b 40 20 40 0.118 0.090 0.048 0.027 c — 30 70 0.127 0.101 0.067 0.047 d — 40 60 0.126 0.099 0.060 0.040 e — 50 50 0.120 0.098 0.050 0.030 f — 60 40 0.125 0.094 0.061 0.045

(69) When comparing EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘a’ and ‘b’ with composition ratios that are not included in EMs of the present disclosure, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes before AA showed BAC from 60 minutes after AAC decreased lower than that of CEs as follows: 21.3% max (EM ‘c’/CE ‘a’=0.100/0.127) 60 min after AAC; 46.9% max (EM ‘c’/CE ‘a’=0.051/0.096) 90 min after AAC; 62.1% max (EM ‘c’/CE ‘a’=0.022/0.058) 150 min after AAC; and 25.9% min (EM ‘a’/CE ‘b’=0.020/0.027) and 71.8% max (EM ‘c’/CE ‘a’=0.011/0.039) 240 min after AAC.

(70) When comparing EMs a through e according to the present disclosure with CEs c through f including only Alnus japonica Steud. stem extract and Sorbus commixta fruit extract as in Korean Patent Registration No. 181168, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes before AA showed BAC from 60 minutes after AAC decreased lower than that of CEs as follows: 1.7% min (EM ‘a’/CE ‘e’=0.118/0.120) and 21.3% max (EM ‘c’/CE ‘c’=0.100/0.127) 60 min after AAC; 4.3% min (EM ‘a’/CE ‘f’=0.090/0.094) and 49.5% max (EM ‘c’/CE ‘c’=0.051/0.101) 90 min after AAC; 4.0% min (EM ‘a’/CE ‘e’=0.048/0.050) and 67.2% max (EM ‘c’/CE ‘c’=0.022/0.067) 150 min after AAC; and 33.3% min (EM ‘a’/CE ‘e’=0.020/0.030) and 76.6% max (EM ‘c’/CE ‘c’=0.011/0.047) 240 min after AAC.

(71) When EMs ‘a’ through ‘e’ according to the present disclosure compared with CE ‘d’ whose composition ratio is closest to that of Dawn 808 the Hangover Solution currently on the market by implementing Korean Patent Registration No. 181168, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes before AA showed BAC from 60 minutes after AAC decreased lower than that of CE as follows: 6.3% min (EM ‘a’/CE ‘d’=0.118/0.126) and 20.6% max (EM ‘c’/CE ‘d’=0.100/0.126) 60 min after AAC; 9.1% min (EM ‘a’/CE ‘d’=0.090/0.099) and 48.5% max (EM ‘c’/CE ‘d’=0.051/0.099) 90 min after AAC; 20% min (EM ‘a’/CE ‘d’=0.048/0.060) and 63.3% (EM ‘c’/CE ‘d’=0.022/0.060) 150 min after AAC; and 50.0% min (EM ‘a’/CE ‘d’=0.020/0.040) and 72.5% max (EM ‘c’/CE ‘d’=0.011/0.040) 240 min after AAC.

(72) 2-4. Results of the 2.sup.nd Test (Specimen Administration 30 Minutes after AAC) are as Follows, as Listed in Table 7.

(73) TABLE-US-00007 TABLE 7 Composition (wt %) BAC (%) C. A. S. 90 min 150 min 240 min ex- ex- ex- after after after tract tract tract AAC AAC AAC EM a 70 10 20 0.094 0.050 0.025 b 70 20 10 0.080 0.032 0.019 c 60 10 30 0.065 0.024 0.014 d 60 20 20 0.072 0.026 0.017 e 50 20 30 0.088 0.045 0.023 CE a 80 10 10 0.101 0.067 0.038 b 40 20 40 0.097 0.052 0.029 c — 30 70 0.109 0.069 0.047 d — 40 60 0.104 0.065 0.033 e — 50 50 0.101 0.054 0.030 f — 60 40 0.106 0.067 0.049

(74) When comparing EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘a’ and ‘b’ with composition ratios that are not included in EMs of the present disclosure, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes after AA showed BAC from 90 minutes after AAC decreased lower than that of CEs as follows: 3.1% min (EM ‘a’/CE ‘b’=0.094/0.097) and 35.6% (EM ‘c’/CE ‘a’=0.065/0.101) 90 min after AAC; 3.8% min (EM ‘a’/CE ‘b’=0.050/0.052) and 64.2% max (EM ‘c’/CE ‘a’=0.024/0.067) 150 min after AAC; and 13.8% (EM ‘a’/CE ‘b’=0.025/0.029) and 63.2% max (EM ‘c’/CE ‘a’=0.014/0.038) 240 min after AAC).

(75) When comparing EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘c’ through ‘f’ including only Alnus japonica Steud. stem extract and Sorbus commixta fruit extract as in Korean Patent Registration No. 181168, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes after before AA showed BAC from 90 minutes after AAC decreased lower than that of CEs as follows: 6.9% min (EM ‘a’/CE ‘e’=0.094/0.101) and 40.4% max (EM ‘c’/CE ‘c’=0.065/0.109) 90 min after AAC; 7.4% min (EM ‘a’/CE ‘e’=0.050/0.054) and 65.2% (EM ‘c’/CE ‘c’=0.024/0.069) 150 min after AAC; and 16.7% min (EM ‘a’/CE ‘e’=0.025/0.030) and 71.4% max (EM ‘c’/CE ‘f’=0.014/0.049) 240 min after AAC).

(76) When EMs ‘a’ through ‘e’ according to the present disclosure compared with CE ‘d’ whose composition ratio is closest to that of Dawn 808 the Hangover Solution currently on the market by implementing Korean Patent Registration No. 181168, EMs of the present disclosure to which the liquid composition specimens were administered 30 minutes after AA showed BAC from 90 minutes after AAC decreased lower than that of CE as follows: 9.6% min (EM ‘a’/CE ‘d’=0.094/0.104) and 37.5% (EM ‘c’/CE ‘d’=0.065/0.104) 90 min after AAC; 23.1% min (EM ‘a’/CE ‘d’=0.050/0.065) and 63.1% max (EM ‘c’/CE ‘d’=0.024/0.065) 150 min after AAC; and 24.2% min (EM ‘a’/CE ‘d’=0.025/0.033) and 57.6% max (EM ‘c’/CE ‘d’=0.014/0.033) 240 min after AAC.

<Experimental Example 3> Survey for Evaluating Hangover Alleviation Effects

(77) Questionnaires were distributed to the test participants at 9 AM the day after the human experiment was performed for evaluating the effects.

(78) 3-1. Evaluation of Hangover Alleviation Effects

(79) Each of the questionnaires presented 7 questions including dizziness alleviation effect, thirsty alleviation effect, fatigue alleviation effect, attention disorder alleviation effect, drowsiness alleviation effect, headache alleviation effect and vomiting alleviation effect and let the participants evaluate the effects on a scale of 1 to 5 (very strong effect=5; moderately strong effect=4; moderate effect=3; moderately week effect=2; and very week effect=1).

(80) 3-2. 1.sup.st Questionnaire

(81) The questionnaire was distributed to the test participants at 9 AM the day after the 1.sup.st clinical test (specimens administration 30 min before AA) were performed for evaluating the effects.

(82) 3-3. 2.sup.nd Questionnaire

(83) The questionnaire was distributed to the test participants at 9 AM the day after the 2.sup.nd clinical test (specimens administration 30 min after AAC) were performed for evaluating the effects.

(84) 3-4. Results of the 1.sup.st Questionnaire are as Follows as Listed in Table 8.

(85) TABLE-US-00008 TABLE 8 Hangover alleviation effects (scores of the questionnaire) Attention Dizziness Thirsty Fatigue disorder Drowsiness Headache Vomiting alleviation alleviation alleviation alleviation alleviation alleviation alleviation Mean EM a 4 4 4 4 4 3 4 3.86 b 4 5 4 4 4 4 4 4.14 c 4 5 4 4 4 5 5 4.43 d 4 5 4 4 4 4 4 4.14 e 4 4 4 4 4 4 4 4.00 CE a 3 3 3 3 3 3 3 3.00 b 3 4 4 3 3 3 3 3.29 c 3 3 3 2 3 3 3 2.86 d 3 3 3 3 3 3 3 3.00 e 3 3 3 3 3 4 3 3.14 f 3 2 3 3 3 3 3 2.86

(86) When the hangover alleviation effects of EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘a’ and ‘b’ with composition ratios that are not included in EMs of the present disclosure, CEs ‘a’ and ‘b’ scored 3.00 to 3.29 of the full scores of 5 while EMs of the present disclosure scored 3.86 to 4.43 on the same scale.

(87) When the hangover alleviation effects of EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘c’ through f including only Alnus japonica Steud. stem extract and Sorbus commixta fruit extract as in Korean Patent Registration No. 181168, CEs ‘c’ through f scored 2.86 to 3.14 of the full scores of 5 while EMs of the present disclosure scored 3.86 to 4.43 on the same scale.

(88) When the hangover alleviation effects of EMs ‘a’ through ‘e’ according to the present disclosure with CE ‘d’ whose composition ratio is closest to that of Dawn 808 the Hangover Solution currently on the market by implementing Korean Patent Registration No. 181168, CE ‘d’ scored 3.00 of the full score of 5 while EMs of the present disclosure scored 3.86 to 4.43 on the same scale.

(89) 3-5. Results of the 2.sup.nd Questionnaire are as Follows as Listed in Table 9.

(90) TABLE-US-00009 TABLE 9 Hangover alleviation effects (point(s) of the questionnaire) Attention Dizziness Thirsty Fatigue disorder Drowsiness Headache Vomiting alleviation alleviation alleviation alleviation alleviation alleviation alleviation Mean EM a 4 4 3 4 4 3 4 3.71 b 4 4 4 4 4 4 4 4.00 c 4 5 4 4 4 4 4 4.14 d 4 4 4 4 4 4 4 4.00 e 4 4 4 4 4 3 4 3.86 CE a 3 3 3 3 3 3 3 3.00 b 3 4 3 3 3 3 3 3.14 c 3 3 3 2 3 3 3 2.86 d 3 3 3 3 3 3 3 3.00 e 3 3 3 3 3 3 3 3.00 f 3 3 3 3 3 3 2 2.86

(91) When the hangover alleviation effects of EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘a’ and ‘b’ with composition ratios that are not included in EMs of the present disclosure, CEs ‘a’ and ‘b’ scored 3.00 to 3.14 of the full scores of 5 while EMs of the present disclosure scored 3.71 to 4.14 on the same scale.

(92) When the hangover alleviation effects of EMs ‘a’ through ‘e’ according to the present disclosure with CEs ‘c’ through ‘f’ including only Alnus japonica Steud. stem extract and Sorbus commixta fruit extract as in Korean Patent Registration No. 181168, CEs ‘c’ through ‘f’ scored 2.86 to 3.00 of the full scores of 5 while EMs of the present disclosure scored 3.71 to 4.14 on the same scale.

(93) When the hangover alleviation effects of EMs ‘a’ through ‘e’ according to the present disclosure with CE ‘d’ whose composition ratio is closest to that of Dawn 808 the Hangover Solution currently on the market by implementing Korean Patent Registration No. 181168, CE ‘d’ scored 3.00 of the full score of 5 while EMs of the present disclosure scored 3.71 to 4.14 on the same scale.